Cara Therapeutics, Inc. announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to TCS for moderate-to-severe pruritus in adult patients with AD. Oral difelikefalin As adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company's decision to discontinue its clinical program in pruritus associated with AD. The Phase 3, two-part, multicenter, randomized, double-blind, placebo-controlled, 12-week study was designed to investigate the use of oral difelikeFalin as adjunctive treatment to topical corticosteroids in approximately 287 patients with AD.

The primary efficacy endpoint was the proportion of patients with a 4-point improvement at Week 12 from baseline in the worst itch numerical rating scale. Oral difelike Falin as adjunct therapy to T CS did not demonstrate a meaningful clinical benefits compared to TCS alone. Oral difelikeFalin was generally well tolerated with a safety profile similar to prior trials.